Kcentra 1,000 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FKKG9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $72,075
Award facts
- Contract value 100% obligated
- $72,075.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a firm fixed-price delivery order valued at $72,075.36 for 1,000 unit vials of Kcentra with an ultimate completion date of January 8, 2026. This award carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. The delivery order was issued under DMS Pharmaceutical Group's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) Indefinite Delivery Contract (SPE2DR), a $499.999 billion contract awarded on November 13, 2025, which positions the company as a regional prime vendor contractor supporting Department of Defense healthcare operations globally through 2036.
Kcentra, a prothrombin complex concentrate used for emergency reversal of warfarin anticoagulation, represents one of the specialized pharmaceutical products within DMS Pharmaceutical Group's extensive portfolio of branded medications, generics, biologics, and medical consumables supplied to military healthcare facilities worldwide. The broader PPV-G GEN V initiative, part of the Defense Logistics Agency's Medical Supply Chain division's $30.3 billion acquisition strategy, enables the issuance of delivery orders to support recurring pharmaceutical needs across the Department of Defense's global healthcare system. DMS Pharmaceutical Group's substantial federal contracting activity and demonstrated performance on numerous previous delivery orders underscore its established role as a critical supplier within the federal pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FKKG9?
SPE2DR26FKKG9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26FKKG9 worth?
The government has obligated $72,075 on SPE2DR26FKKG9.
Is contract SPE2DR26FKKG9 an order under another contract?
Yes. SPE2DR26FKKG9 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKG9 competed?
The extent of competition for SPE2DR26FKKG9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award